We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

U.S. Listing | Biotechnology company CARGO officially lists on NASDAQ in the United States, raising $281 million!

U.S. Listing | Biotechnology company CARGO officially lists on NASDAQ in the United States, raising $281 million!

Golden Box Group | Listing Guidance | US Listing |IPO |SPAC |RTO | US Listing | Professional US Listing Guidance Institution | US Stock Listing |

US Listing News Today's Quick Review!

395162791280dddacac215a5b4f45d8b_640_wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1.png

On November 10, 2023, biotechnology company CARGO Therapeutics (ticker symbol: CRGX) officially listed on the NASDAQ in the United States.

The offering price of CARGO Therapeutics was $15, with 18.75 million shares issued, raising a total of $281 million.

The opening price of CARGO Therapeutics was $15.73, representing a 4.87% increase from the offering price. Calculated at the opening price, CARGO Therapeutics had a market capitalization of $608 million.

845c6246695ccdb1b978baa8db3655b6_640_wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1.png

CARGO Therapeutics was founded in 2021, dedicated to developing "next-generation" cell therapies. It was co-founded by Crystal Mackall, a cell therapy scholar from Stanford University, who is the founding director of the Stanford Cancer Cell Therapy Center and director of the Stanford Parker Institute for Cancer Immunotherapy, and has served on the scientific advisory boards of multiple biotechnology and pharmaceutical companies. Other founders are mostly scholars from Stanford University School of Medicine.

CRG-022 is CARGO Therapeutics' current main candidate drug, constructed by transducing autologous T cells with a lentiviral vector (m971-BBZ) expressing a CD22-targeted CAR. Currently, CRG-022 is in Phase I clinical trials, with interim results showing that for 38 patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) after CD19 CAR-T cell therapy, the complete response (CR) and overall response rate (ORR) reached 53% and 68% respectively.

CARGO Therapeutics' pipeline also includes Multi-Specific CAR-T, which aims to overcome multiple cancer resistance mechanisms and treat various hematological malignancies through a multi-target approach.

a7e2f73900c3633d7c112ebb14adb9e9_640_wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1.png

CARGO Therapeutics currently has no revenue. For the 2021-2022 fiscal years, the company's net profit was -5.85 million USD and -40.951 million USD respectively.

f7902f4b0cb87ace27abcd3fe6248044_640_wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1.png

Chinese concept stocks' US listings are warming up,the approval process for overseas issuance and listing filings of enterprises has accelerated,the US stock market performed strongly in 2023,and Chinese companies' confidence in listing in the US is growing. Jinhe Group's Xiaojin will share daily hot information on US listings to help enterprises soar in their listings!

Disclaimer: Some information in this article is sourced from the internet. The content of this article is for sharing purposes only. If there are any content or copyright issues, please contact us and we will handle them as soon as possible.

尾图新.jpg

Originally published on 金盒企业管理集团